CSL Ltd. — M&A Activity 2009

May 6, 2009

For immediate release

==> picture [205 x 32] intentionally omitted <==

==> picture [59 x 30] intentionally omitted <==

==> picture [262 x 27] intentionally omitted <==

PROPOSED ACQUISITION OF TALECRIS BIOTHERAPEUTICS – MARKET SPECULATION

Melbourne, Australia (7 May 2009) - CSL Limited has become aware of market and media speculation regarding the proposed acquisition of Talecris Biotherapeutics, Inc. This matter is currently being considered by the U.S. Federal Trade Commission (FTC), including the potential for remedies. This development is not unusual and provides no indication that the deal will, or will not, proceed, or the timing of an FTC decision.

CSL will immediately notify the Australian Stock Exchange as and when it is aware of the decision by the FTC.

For more information about CSL Limited, visit www.csl.com.au

Investor Contact:

Mark Dehring Director of Investor Relations Phone: 61 3 9389 2818 Email: mark.dehring@csl.com.au

==> picture [98 x 7] intentionally omitted <==